Golden
Evox Therapeutics

Evox Therapeutics

An exosome therapeutics company founded in 2016 and based in Oxford, UK, that uses exosomes to deliver small and large molecule therapeutics. The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.

Evox Therapeutics is a biotechnology company developing exosome therapeutics using exosomes, cell-derived vesicles, to deliver small and large molecule therapeutics. The company is headquartered in Oxford, Oxfordshire, United Kingdom and was founded in 2016 by Per Lundin.



The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.Evox Therapeutics has built an intellectual property portfolio encompassing key aspects of extracellular vesicle-based nucleic acid and protein delivery technology. 

Funding

Series A

On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation. 

Series B

On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures. 

Grant - Duchenne UK

On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand. 

Grant - Innovative UK

On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million. 



Timeline

March 22, 2019

Grant - Innovative UK

On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million. 

November 18, 2018

Grant - Duchenne UK

On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand. 

September 2, 2018

Series B funding round

On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures. 

May 16, 2016

Series A funding round

On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation. 

People

Name
Role
Related Golden topics







Further reading

Title
Author
Link
Type
Date

Duchenne UK Awards £655K to Evox Therapeutics to Develop New Way of Gene Therapy Delivery

Vijaya Iyer

Web



Evox Therapeutics Named in The Sunday Times Fast Track Disruptors to Watch

Evox Therapeutics

Web



Evox Therapeutics secures £35.5m Series B - Oxford University Innovation

Innovative UK

Web



Documentaries, videos and podcasts

Title
Date
Link

Duchenne UK and Evox Therapeutics, An interview with Professor Matthew Wood

November 13, 2018

LSX World Congress 2019 Presentations - Evox Therapeutics

February 12, 2019

Companies

Company
CEO
Location
Products/Services









References